Literature DB >> 23943668

Management of anemia in patients receiving triple therapy for hepatitis C.

A Sidney Barritt1.   

Abstract

Entities:  

Year:  2013        PMID： 23943668      PMCID： PMC3740809     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Authors:  Alexander J Thompson; Rosanna Santoro; Valeria Piazzolla; Paul J Clark; Susanna Naggie; Hans L Tillmann; Keyur Patel; Andrew J Muir; Kevin V Shianna; Leonardo Mottola; Daniela Petruzzellis; Mario Romano; Fernando Sogari; Domenico Facciorusso; David B Goldstein; John G McHutchison; Alessandra Mangia
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

Review 2.  Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.

Authors:  A Sidney Barritt; Michael W Fried
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

Authors:  Yuki Hitomi; Elizabeth T Cirulli; Jacques Fellay; John G McHutchison; Alexander J Thompson; Curtis E Gumbs; Kevin V Shianna; Thomas J Urban; David B Goldstein
Journal:  Gastroenterology       Date:  2011-01-01       Impact factor: 22.682

4.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Authors:  Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; David Pound; Mitchell N Davis; Joseph S Galati; Stuart C Gordon; Natarajan Ravendhran; Lorenzo Rossaro; Frank H Anderson; Ira M Jacobson; Raymond Rubin; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Eirum Chaudhri; Janice K Albrecht
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

5.  Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis.

Authors:  Paola Mancino; Katia Falasca; Claudio Ucciferri; Eligio Pizzigallo; Jacopo Vecchiet
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-03-31       Impact factor: 2.576
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.